Moderna 2022 Priorities and Capital Allocation

Forward-looking statements and Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: anticipated sales under advanced purchase agreements in 2022 and the associated dollar amounts to be received, which should not be construed as expected 2022 revenue; Moderna's ongoing discussions regarding additional advanced purchase agreements; COVID market dynamics and anticipated timing of sales in 2022; the ability of the Moderna COVID-19 Vaccine to provide protection against COVID-19 over time, including against evolving variants of concern; Moderna's receipt of data and ability to go to market with mRNA-1273.214; Moderna's ability to quickly accelerate vaccine candidates into pivotal studies; Moderna's expectations regarding the evolution of SARS-CoV-2 and the timing for a transition into an endemic phase; the estimated market opportunity for endemic COVID booster vaccines; the potential for bi- and multi-valent boosters to provide broad immunity; expected timing of trials of Moderna's flu and combination vaccine candidates; timing of new data on Moderna's development candidates in rare genetic diseases and oncology; capital allocation; Moderna's 2022 financial framework; and Moderna's agreements and ongoing discussions with countries regarding service/subscription contracts, including its committed agreements with Australia and Canada. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this presentation. Slide 2 moderna

View entire presentation